stockrowIDEXX Laboratories, Inc.
IDXX Healthcare Diagnostics & Research
IDEXX Laboratories, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $4.3 billion, up 10.4% from fiscal 2024.
- Revenue
- +9.86%
- EPS
- +17.3%
- Free cash flow
- +17.6%
- Total debt
- −28.6%
Quarter to September 2026, against a year earlier
Follow IDXX
Alert me
IDEXX Laboratories, Inc. (IDXX) Net income
IDEXX Laboratories, Inc.'s net income for fiscal 2025 was $1.1B, up 19.3% from $887.9M in fiscal 2024. Over the twelve months to 30 September 2026 it was $1.2B. Over the past ten years it has ranged from $192.1M (fiscal 2015) to $1.1B (fiscal 2025) — the current reading is the highest in ten years. Net income has risen for 3 consecutive fiscal years. IDEXX Laboratories, Inc. ranks 5th of 49 Diagnostics & Research companies by net income.
Net income, annual
Embed this chart
Annual newest first
| Period | Net income | Change |
|---|---|---|
| FY2025 | $1.1B | 19.33% |
| FY2024 | $887.9M | 5.07% |
| FY2023 | $845.0M | 24.44% |
| FY2022 | $679.1M | (8.83%) |
| FY2021 | $744.8M | 27.95% |
| FY2020 | $582.1M | 36.08% |
| FY2019 | $427.8M | 13.46% |
| FY2018 | $377.0M | 43.22% |
| FY2017 | $263.3M | 18.56% |
| FY2016 | $222.1M | 15.57% |
Quarterly newest first
| Period | Net income | Change |
|---|---|---|
| Sep 2026 | $317.1M | (6.28%) |
| Jun 2026 | $338.4M | 21.54% |
| Mar 2026 | $278.4M | 12.19% |
| Dec 2025 | $248.2M | (9.62%) |
| 43 more quarters | Free account |
Against its own ten years
Net income against peers
| Company | Net income |
|---|---|
| A Agilent Technologies, Inc. compare | $1.4B |
| IQV IQVIA Holdings Inc. compare | $1.4B |
| IDXX IDEXX Laboratories, Inc. | $1.2B |
| DGX Quest Diagnostics Incorporated compare | $1.2B |
| LH Labcorp Holdings Inc. compare | $1.0B |
| MTD Mettler-Toledo International, Inc. compare | $905.6M |
| ILMN Illumina, Inc. compare | $895.0M |
| WAT Waters Corporation compare | $98.2M |
| NTRA Natera, Inc. compare | −$164.7M |
What Net income is
Net Income tells an investor how much profit a company kept in a period after every cost, interest charge and tax.
Reported line item
More on IDXX
- Revenue
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement